Freedom of Information request on pregnancy and the AstraZeneca COVID-19 vaccine (FOI 21/726)
Published 29 December 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-26-july-2021/freedom-of-information-request-on-pregnancy-and-the-astrazeneca-covid-19-vaccine-foi-21726
27th July 2021
FOI 21/726
Dear
Thank you of your email dated 26th June 2021, where you requested the following:
Please advise how many first and second doses of AstraZeneca coronavirus vaccine have been administered to pregnant women. Please advise of the gestation at which both the first and second doses have been reported, broken down at least by trimester. Have any cases of VITT or fatality following vaccination been reported in pregnant women receiving the AstraZeneca coronavirus vaccine.
Regarding your first question, the MHRA does not hold information relating to how many vaccinations have been administered. You may wish to contact Public Health England at [email protected] as they may be able to help with this part of your request.
We can confirm that up to 21st July 2021, the MHRA has not received any Yellow Card reports of blood clots with concurrent low platelets in pregnant women following vaccination with COVID-19 Vaccine AstraZeneca. We can also confirm that we have not received any Yellow Card reports of fatalities in pregnant women following vaccination with the COVID-19 Vaccine AstraZeneca.
Public Health England have published a guide for women who are pregnant, breastfeeding or of childbearing age. This can be accessed using the following link:
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division